Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 1 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
 
 
Sponsor –Investigators Jane E. Gros s, MD PhD and Jerry A. Nick, MD 
 
Clinical Research Protocol 
Healthcare-associated links in transmission of nontuberculous mycobacteria among 
patients with cystic fibrosis 
Protocol Number: HALT NTM 
Version Date: May 8, 2020 
Sponsor-Investigator: Jane E. Gross, MD PhD 
National Jewish Health 
 
Jerry A. Nick, MD 
National Jewish Health 
Funding Organization: Cystic  Fibrosis Foundation (CFF) 
Coordinating Center: National Jewish Health 
Denver, CO 80206 
Telephone: (303) 398 – 1876 
Fax: (202) 270 – 2189 
 
Approval : 
 
 
Jane E. Gross, MD PhD Date 
 
 
Approval : 
 
 
Jerry A. Nick, MD Date 
 
 
The information in this document may not be disclosed unless federal or state law or regulations require such 
disclosure. Subject to the foregoing, this information may be disclosed on ly to those persons involved in the 
study who have a need to know, with the obligation not to further disseminate this information. These 
restrictions on disclosure will apply equally to all futu re oral or written information, supplied to you by the 
Cystic Fibrosis Foundation or its designees, which is designated as "privileged" or "confidential". 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 2 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
PROTOCOL AGREEMENT 
 
I have read the protocol specified below. In my formal capacity as Investigator, my duties 
include ensuring the safety of the study participants enrolled under my supervision and providing 
the Sponsor-Investigators with complete and timely information, as outlined in the protocol. It is 
understood that all information pert aining to the study will be held strictly confidential and that 
this confidentiality requirement applies to all stu dy staff at this site. Furthermore, on behalf of 
the study staff and myself, I agree to maintain th e procedures required to  carry out the study in 
accordance with accepted GCP principles and to  abide by the terms of this protocol. 
 
Protocol Number: HALT NTM 
 
Protocol Title: Healthcare-associated links in transmission of nontube rculous mycobacteria 
among patients with cystic  fibrosis (HALT NTM) 
 
Protocol Date: May 8, 2020 
 
 
 
 
Investigator Signature Date 
 
 
Print Name and Title 
Site #: 
Site Name: 
Address: 
 
 
 
 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 3 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
TABLE OF CONTENTS 
1 BACKGROUND  ............................................................................................................................... ........... 11 
1.1 OVERVIEW  OF NON‐CLINICAL STUDIES ............................................................................................................................... ...............  12 
1.2 OVERVIEW  OF PRELIMINARY  STUDIES ............................................................................................................................... .................  13 
2. STUDY RATIONALE  ...............................................................................................................................  15 
2.1 RISK / BENEFIT ASSESSMENT  ............................................................................................................................... ...............................  18 
3 STUDY OBJECTIVES  ............................................................................................................................... .... 18 
3.1 PRIMARY OBJECTIVE ............................................................................................................................... .............................................  18 
3.2 SECONDARY  OBJECTIVES  ............................................................................................................................... ......................................  18 
4 STUDY DESIGN ............................................................................................................................... .......... 19 
4.1 STUDY OVERVIEW  ............................................................................................................................... .................................................  19 
5 CRITERIA  FOR EVALUATION  ......................................................................................................................  19 
5.1 PRIMARY ENDPOINT  ............................................................................................................................... .............................................  19 
5.2 SECONDARY  ENDPOINTS  ............................................................................................................................... .......................................  19 
6 PARTICIPANT  SELECTION  ..........................................................................................................................  20 
6.1 STUDY POPULATION  ............................................................................................................................... .............................................  20 
6.2 INCLUSION  CRITERIA ............................................................................................................................... .............................................  20 
6.3 EXCLUSION  CRITERIA ............................................................................................................................... ............................................  20 
6.4 STUDY SPECIFIC TOLERANCE  FOR INCLUSION /EXCLUSION  CRITERIA .................................................................................................  20 
6.5 SCREEN FAIL CRITERIA ............................................................................................................................... ..........................................  20 
7 CONCURRENT  MEDICATIONS  ....................................................................................................................  20 
7.1 ALLOWED MEDICATIONS  AND TREATMENTS  ............................................................................................................................... ....... 20 
7.2 PROHIBITED  MEDICATIONS  AND TREATMENTS  ............................................................................................................................... ... 20 
8 STUDY TREATMENTS  ............................................................................................................................... . 20 
9 STUDY PROCEDURES  AND GUIDELINES  .....................................................................................................  21 
9.1 CLINICAL ASSESSMENTS  ............................................................................................................................... ........................................  21 
9.2 CLINICAL LABORATORY  MEASUREMENTS  ............................................................................................................................... ............ 21 
9.3 RESEARCH LABORATORY  MEASUREMENTS  ............................................................................................................................... ......... 21 
10 EVALUATIONS  BY VISIT .............................................................................................................................  21 
11 ADVERSE  EXPERIENCE  REPORTING  AND DOCUMENTATION  ......................................................................  21 
12 DISCONTINUATION  AND REPLACEMENT  OF PARTICIPANTS  .......................................................................  22 
12.1 EARLY WITHDRAWAL  OF PARTICIPANTS  FROM THE STUDY ...............................................................................................................  22 
12.2 REPLACEMENT  OF PARTICIPANTS  ............................................................................................................................... .........................  22 
13 PROTOCOL  VIOLATIONS  ...........................................................................................................................  22 
14 DATA SAFETY MONITORING  .....................................................................................................................  22 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 4 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
 15 STATISTICAL  METHODS  AND CONSIDERATIONS  ........................................................................................  22 
15.1 GENERAL CONSIDERATIONS  ............................................................................................................................... .................................  22 
15.2 DEMOGRAPHIC  AND BASELINE CHARACTERISTICS  .............................................................................................................................  23 
15.3 ANALYSIS OF PRIMARY ENDPOINT  ............................................................................................................................... .......................  23 
15.4 ANALYSIS OF SECONDARY  ENDPOINTS....................................................................................................................... .........................  23 
15.5 INTERIM ANALYSIS ............................................................................................................................... ................................................  23 
15.6 SAMPLE SIZE ............................................................................................................................... .........................................................  24 
16 DATA COLLECTION,  RETENTION  AND CLINICAL MONITORING  ....................................................................  24 
16.1 DATA COLLECTION  INSTRUMENTS  ............................................................................................................................... .......................  24 
16.2 DATA MANAGEMENT  PROCEDURES  ............................................................................................................................... ....................  24 
16.3 SECURITY AND ARCHIVAL OF DATA ............................................................................................................................... ......................  25 
16.4 AVAILABILITY  AND RETENTION  OF INVESTIGATIONAL  RECORDS ........................................................................................................  25 
16.5 MONITORING  ............................................................................................................................... ........................................................  25 
16.6 PARTICIPANT  CONFIDENTIALITY  ............................................................................................................................... ...........................  25 
17 ADMINISTRATIVE,  ETHICAL, REGULATORY  CONSIDERATIONS  ...................................................................  25 
17.1 PROTOCOL  AMENDMENTS  ............................................................................................................................... ...................................  26 
17.2 INSTITUTIONAL  REVIEW BOARDS AND INDEPENDENT  ETHICS COMMITTEES  ....................................................................................  26 
17.3 INFORMED  CONSENT FORM ............................................................................................................................... .................................  26 
17.4 CONSENT FOR COLLECTION  AND USE OF CFF REGISTRY ID NUMBER ..............................................................................................  26 
17.5 PUBLICATIONS  ............................................................................................................................... .......................................................  27 
17.6 INVESTIGATOR  RESPONSIBILITIES  ............................................................................................................................... .........................  27 
18 REFERENCES  ............................................................................................................................... ..............  28 
APPENDIX  1: COLORADO ‐RESEARCH  DEVELOPMENT  PROGRAM  NTM ISOLATE RESULT LETTER ..........................  31 
APPENDIX  2. REDCAP USER GUIDE .....................................................................................................................34  
APPENDIX  3 ENVIRONMENTAL  SAMPLING  PROTOCOL  ......................................................................................  37 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 5 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
 LIST OF ABBREVIATIONS AND ACRONYMS 
 
 
AE Adverse event 
CFR Code of Federal Regulations 
CFTR Cystic fibrosis transmembrane conductance regulator 
CF Cystic fibrosis 
CFF Cystic Fibrosis Foundation 
CFF PR CFF Patient Registry 
CO-RDP Colorado Research Development Program 
DMC Data Monitoring Committee 
DSMB Data Safety Monitoring Board 
EDC Electronic data capture 
FDA Food and Drug Administration 
GCP Good Clinical Practice 
HIPAA Health Insurance Portability and Accountability Act of 1996 
IP&C Infection prevention and control 
ICH International Conference on Harmonisation 
IEC Independent Ethics Committee 
IRB Institutional Review Board 
MAC M. avium complex 
NTM Nontuberculous mycobacteria 
PI Principal Investigator 
REDCap Research Electronic Data Capture 
TDNCC Therapeutics Development Ne twork Coordinating Center 
WGS Whole genome sequencing 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 6 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
PROTOCOL SYNOPSIS 
 
TITLE Healthcare-associated links in transmission of nontuberculous 
mycobacteria among patients with cystic fibrosis (HALT NTM) 
SPONSOR- 
INVESTIGATOR Jane E. Gross, MD PhD 
Jerry A. Nick, MD 
FUNDING 
ORGANIZATION Cystic Fibrosis Foundation (CFF) 
NUMBER OF SITES Up to 20 
RATIONALE Pulmonary NTM infection is rec ognized as one of the most 
challenging infections to treat among CF patients, notable for 
prolonged treatment courses and of ten poor response to therapy. 
Positive cultures for NTM occur in about 20% of children and adults 
with CF. However, the source of NTM infection, modes of 
transmission, and exposure risks are poorly understood. It is thought 
that NTM is primarily acquired fr om environmental sites including 
soil and water as well as water supply systems to homes, hospitals, and clinics and from aerosols gene rated by flowing water from taps, 
showers, and fountains. Nonetheles s, no direct molecular link has 
been established between environmental NTM and respiratory CF NTM. Healthcare-associated tran smission of NTM among CF patients 
has been suspected and is of growing concern for CF Centers 
worldwide. Widespread global tran smission of NTM, potentially via 
person-to-person transmission of fomites and aerosols has been 
reported, but no standardized epidem iologic investigation tool for 
healthcare-associated NTM ac quisition has been published. 
STUDY DESIGN PART A / Epidemiolo gic Investi gation: 
The CO-RDP provides a national re ference laboratory for CF NTM. 
NTM respiratory isolates received  from CF Care Centers around the 
U.S. undergo culture, molecular identification, antimicrobial 
susceptibility, and whole genome sequencing (WGS). Using this approach, the CO-RDP has identified clusters of NTM isolates, 
defined as highly similar strains at the genomic level, harbored by two 
or more CF patients who are cared for at the same CF Care Center. 
These identifications have height ened our concern for potential 
healthcare-associated NTM acquisiti on originating from patient-to- 
patient transmission or a comm on environmental source within 
Centers. Using integrated clinical and epid emiological research methods, the 
HALT NTM retrospective epidemiol ogic investigation can identify 
overlaps in source(s) of care betw een patients with highly similar 
NTM isolates in a Center. The HALT NTM toolkit facilitates a 
stepwise process by which individu al Centers perform retrospective 
epidemiologic evaluation of patients identified by the CO-RDP as part 
of an NTM cluster. HALT NTM is available to the entire CF 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 7 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
 
 Foundation Care Network, under a collabo rative agreement, to initiate 
a standardized, independent, conf idential, internal NTM outbreak 
investigation. A control comparison group will also be investigated. 
 
PART B / Water Biofilm Collection : 
Clustered NTM isolates could orig inate from a shared healthcare 
water source. Biofilms from healthcare water supplies will be collected and NTM recovered, identified, and sequenced to determine if the respiratory CF NTM strain  genotype is similar to those 
recovered from the healthcare water supply. 
PARTICIPANT 
STUDY DURATION PART A/ Epidemiologic Investigation: 
CF Centers will be eligible for enrollment as NTM clusters are 
identified by the CO-RDP. The total duration of the study and 
analysis is 3 years. 
 
PART B / Water Biofilm Collection: 
CF Centers will be eligible for enrollment as NTM clusters are identified by the CO-RDP. The total duration of the study and 
analysis is 3 years. 
PRIMARY OBJECTIVE PART A / Epidemiolo
gic Investi gation: 
Our primary objective is to implem ent a standardized epidemiologic 
investigation, via the HALT NTM t ool kit, in CF Care Centers 
identified as having clusters of highly similar NTM isolates. We will assess the origins and prevalence of  healthcare associated patient to 
patient transmission of NTM among different CF Care Centers. We 
will characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting. 
 
PART B / Water Biofilm Collection: 
The primary objective is to determine if NTM strains identified in 
clusters are related to strains isol ated from water biofilm sources in 
the CF healthcare setting. Because hospital and clinic plumbing 
sources could pose a risk to CF patients, we aim to perform WGS of 
NTM isolates from healthcare biof ilms obtained from CF Centers 
with NTM clusters among patients to determine if the biofilm isolates 
are highly related to the isol ates recovered from patients. 
SECONDARY 
OBJECTIVES PART A / Epidemiolo gic Investi gation: 
The secondary objectives are to: 
 Assess degree of proximity of subj ects in time and/or space. 
 Compare the relationship between similarity of strains and 
degree of proximity of subjects. 
 Model the relationship between the degree of similarity and 
strains with the proximity and subject characteristic variables. 
PART B / Water Biofilm Collection: 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 8 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
 
 The secondary objectives are to: 
 Characterize clinically-relevant NTM isolates and healthcare 
biofilms. 
 Describe most common biofilm s ources within the healthcare 
setting harboring clinically  relevant NTM isolates. 
NUMBER OF 
PARTICIPANTS PART A / Epidemiolo gic Investi gation: 
Unlimited and based on the number of patients identified in an NTM 
cluster within an individual CF Care Center (prospectively collected data). Two controls will be identified  for every subject within a cluster. 
 
PART B / Water Biofilm Collection: N/A 
PARTICIPANT 
SELECTION CRITERIA: 
Inclusion Criteria PART A / Epidemiologic Investigation: 
Inclusion Criteria: 
1. Written informed consent is not required for this retrospective 
epidemiological study. 
 2. Diagnosis of CF consistent  with the 2017 CFF guidelines. 
 3. Male or female participant of any age who have a history of NTM 
species or sub-species collected from expectorated sputum, 
induced sputum and/or bronchoalv eolar lavage and identified by 
the CO-RDP as falling into a highly -related cluster within a single 
CF Care Center. 
 4. Controls subjects are male or fe male participants of any age who 
have a history of NTM species or sub-species collected from 
expectorated sputum, induced s putum and/or bronchoalveolar 
lavage and identified by the CO -RDP as NOT falling into a 
highly-related cluster within a single CF Care Center. 
 
PART B / Water Biofilm Collection: 
 Inclusion Criteria: 
 N/A 
PARTICIPANT PART A / Epidemiologic Investigation: 
SELECTION 
CRITERIA: N/A 
Exclusion Criteria PART B / Water Biofilm Collection: 
 N/A 
CONCOMMITANT 
MEDICATIONS Allowed: N/A 
Prohibited: N/A 
PRIMARY PART A / Epidemiologic Investigation: 
ENDPOINT Identification of a shared healthcare-associated source(s) between 
 patients in a CF Care Center. 
 PART B / Water Biofilm Collection: 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 9 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
 
 Identification of biofilm is olates that are highly related to the isolates 
recovered from patients. 
SECONDARY 
ENDPOINTS PART A / Epidemiologic Investigation: 
The secondary endpoints are: 
 Incidence and prevalence of CF NTM species/subspecies by 
geographical region. 
 
PART B/ Water Biofilm Collection: 
The secondary endpoints are: 
 Incidence and prevalence of healthcare-associated water 
biofilm NTM species/subspecies by geographical region. 
EXPLORATORY 
EVALUATIONS None 
PLANNED INTERIM 
ANALYSIS No formal interim analysis involving a data monitoring committee 
(DMC) is planned. 
STATISTICS 
PRIMARY 
ANALYSIS PLAN PART A / Epidemiologic Investigation: 
For the primary endpoint, biostatistica l analysis of the multicenter data 
will be completed using both qualitative and quantitative approaches. We will identify a set of variables used to assess degree of proximity of subjects in time and/or space.  For example, two subjects with 
neighboring rooms at a hospital would have close proximity, but proximity would be increased for tw o subjects at a f acility that had 
longer overlap time, relative to a pair of subjects that had shorter overlap. We will explore creating co mposite measures of quantitative 
proximity that incorporate multiple variables. Qualitative measures of proximity, such as location type (t esting laboratory, patient room) will 
also be assessed. Several testing appr oaches will  be used to compare 
the relationship between similarity of strains and degree of proximity 
of subjects. In the simplest form, de scriptive statistics will be computed 
for proximity variables, for pairs of  subjects who are determined to 
have similar strains versus those who have dissimilar strains, and 
multivariate or 2-sample t-tests will be performed to test for differences between these groups. More advanced modeling will be performed to determine the relationship between the degree of similarity in strains with the proximity and subject characteristic variables; multiple linear regression will be used when considering continuous strain similarity, while multiple logistic regression will be used when considering subjects with dichotomized (sim ilar/dissimilar) strains to other 
subjects. 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 10 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
 
 PART B / Water Biofilm Collection: 
Several testing approaches will be used to compare the relationship 
between similarity of strains between the clustered patients and environmental isolates. Descriptive statistics will be computed for 
proximity variables, fo r pairs of subjects and environmental isolates 
that are determined to have sim ilar strains versus those who have 
dissimilar strains, and multivariate or 2-sample t-tests will be performed to test for differences between these groups. 
RATIONALE FOR 
NUMBER OF 
PARTICIPANTS The CO-RDP provides a national refe rence laboratory for CF NTM. 
NTM respiratory  isolates received  from CF  Care Centers around the 
U.S. undergo culture, molecular identification, antimicrobial 
susceptibility, and WGS. Using this approach, the CO-RDP has identified clusters of NTM isolates, defined as highly similar strains at 
the genomic level, harbored by two or more CF patients who are cared for at the same CF Care Center. All CF Centers, found to have clusters 
of highly-related NTM is olates will be offered enrollment. Subject 
enrollment is unlimited and based on the number of patients identified  
in an  NTM  cluster  within an  individual  CF  Care Center 
(prospectively collected data). 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 11 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
 
 
1 BACKGROUND 
Healthcare-associated transmission of NTM Pulmonary nontuberculous mycobacteria (NTM) infe ction is recognized as one of the most 
challenging infections to treat am ong cystic fibrosis (CF) patien ts, notable for prolonged treatment 
courses and often poor response to therapy.
1,2 Positive cultures for NTM occur in  about 20% of 
children and adults with CF.3 However, the source of NTM infec tion, modes of transmission, and 
exposure risks are poorly understood. It is th ought that NTM is primarily acquired from 
environmental sites including soil and water as well as water supply systems to homes, hospitals, 
and clinics and from aerosols generated by flow ing water from taps, showers, and fountains.4-6 
Nonetheless, no direct molecular link has b een established between environmental NTM and 
respiratory CF NTM.7 Healthcare-associated transmission of  NTM among CF patients has been 
suspected8-10 and is of growing concern for CF Centers worldwide. Bryant et al. reported 
widespread global transmission of NTM, potentially  via person-to-person transmission of fomites 
and aerosols,11 but no standardized epidemiologic invest igation tool for healthcare-associated 
NTM acquisition has been published. 
CO-RDP serves as a national reference laboratory for CF NTM 
The Colorado Research Development Program (CO- RDP) provides a national reference laboratory 
for CF NTM.12 NTM respiratory isolates received  from CF Care Centers around the 
U.S. undergo culture, molecular identification, antimicrobial susceptibility, and whole genome 
sequencing (WGS).13 Using this approach, the CO-RDP has id entified clusters of NTM isolates, 
defined as highly similar strains at the genomic level, harbored by two or more CF patients who 
are cared for at the same CF Care Center. These identifications have heightened our concern for 
potential healthcare-associated NT M acquisition originating from patient-to-patient transmission 
or a common environmental source within Centers. 
Identification of highly similar clust ers of NTM within the care center network 
Analysis of the 2016 CF Foundation (CFF) Patient  Registry Annual Data Report found 20% of 
patients cultured for NTM between 2012-2016 ha d a NTM species isolated at least once.17 In 2017, 
of the 15,041 CF patients in the national registry  who had an NTM culture performed that year, 
1,903 (12.7%) had an NTM species isolated one or more times.18 The modes of acquisition of NTM 
in CF remain unclear ( Figure 1 ). 
The CO-RDP comprises multiple coordinated 
cores which receive, bank, culture, sequence, and analyze NTM clinical isolates from CF clinics 
around the U.S. Extracted NTM DNA from 
received samples is sequenced via WGS and analyzed for phylogenetic  relatedness. As of 
January 2019, 123 facilities across the nation have 
submitted CF NTM isolates that have been sequenced. Phylogenetic data of NTM isolates 
from CF patients in the U.S. ( Figure 2 ), as well  as 
reference and environmental stains worldwide, are being collected in an ongoing fashion by the CO-
RDP, and we found that highly similar NTM 
strains are shared within  individual Care Centers 
(Figure 3 ) as well as between geographically 
 
 
Figure 1 : Possible modes of NTM 
transmission. 
 
 
  
 
  
 
 
 
 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 12 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
 
distant Centers. This work is clinically significant 
because a shared highly si milar strain within a 
healthcare setting suggests common environmental 
sources of acquisition or  patient- to-patient 
transmission.9 
To define relatedness, the CO-RDP has examined 
the range of single-nucl eotide polymorphism 
(SNP) differences among isolates from different 
patients compared to longitudinal isolates from the same patients over time to establish an evidence-
based SNP threshold that is consistent with a clonal 
or highly similar strain within each NTM 
species.
13,19 As this genomic database expands, 
thresholds of similarity will be refined through continued acquisition of longitudinal isolates 
collected from patients. Together, the inter- and 
intra-patient information defines a threshold to initiate an epidemiologi c investigation. As the 
number of SNPs between strains increases, the 
likelihood of shared or igin decreases. SNP 
threshold numbers are also dependent on the size 
of the core genome used to assess similarity. The 
CO-RDP utilizes WGS and phylogenomic analysis to examine the population structure and diversity 
of each NTM species and subspecies, and to 
identify clustered strain s that are phylogenetically-
related and nearly identi cal at the core genome 
level. Using the CO-RDP data driven 
methodology, a threshold of 15 SNP for M. 
abscessus ssp. abscessus (MAB) is stringent, 
reliable and provides an optimal approach  to assess similarity between isolates.
13,19 
 
Multiple reports concerning healthcare associat ed outbreaks of NTM among CF patients continue 
to appear in the literature.8-10 Despite the reports, no standardized approach to epidemiologic 
investigation has been established for examina tion of healthcare-associated CF NTM outbreaks. 
Criteria must be met to validate NTM disease transmission.20 NTM bacterial isolates must be 
genetically-matched between the patient and e nvironment or between patients. Evidence of 
epidemiologic exposure and potential cross-infection must exist. Currently, WGS is the gold 
standard for NTM isolate comparison and was used in the study at Papworth Hospital to assess 
transmission of NTM between CF patients.9 The authors examined WGS on 168 consecutive 
isolates of M. abscessus from 31 adult CF patients in a Cent er from 2007-2011. Using core genome 
SNP analysis, they identified highly similar (<25 SNP) clusters of M. abscessus massiliense 
(MMAS) isolates from patients who demonstr ated opportunities for cross- infection via 
overlapping clinic visits using epidemiological  data and contact investigation. The authors 
concluded substantial evid ence existed to support healthcare-acquired transmission . One smaller 
study utilized a similar approach to evaluate hi ghly similar NTM isolates, but the data did not 
support healthcare-associated transmission of infection.21 
 
 
1.1 Overview of Non-Clinical Studies 
Not Applicable  
M. abscessus  subsp. abscessus  
M. avium 
M. abscessus  subsp. massiliense  
M. intracellulare  
M. chimaera  
M. spp. (unknown)  
M. abscessus  subsp. bolletii 
M. chelonae 
M. asiaticum  
M. kubicae 
M. arupense  
Figure 2 : CF NTM isolates sequenced by the 
CO-RDP. 
 
 
 
Figure 3 : CO-RDP identified NTM clusters 
within 10 CF Care Centers. 

Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 13 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
1.2 Overview of Preliminary Studies 
When the CO-RDP receives NTM c linical isolates from around the U.S., DNA is sequenced via 
WGS and analyzed for genetic relatedness at th e core genome level. Mycobacterial DNA is 
sequenced using Illumina MiSeq 2X300 chemistry. Sequence reads are mappe d to the appropriate 
mycobacterial reference genome and compared to find phylogenomic differences at the SNP level. 
As of January 2019, over 1,000 CF NTM isolates from  631 patients at 92 c ontributing facilities 
have been banked . To date, 904 CF NTM isolates have been sequenced from 79 U.S. Care 
Centers, representing a total of 13 predominant NTM species and subspecies (Figure 2 ). To 
determine a threshold of genetic similarity for hi ghly similar isolates, pair wise SNP distances in 
the core genome were calculated between all pa irs of “same” (within- patient) or “different” 
(between-patient) isolates. We obs erved that 25 or fewer SNPs define background similarity of 
same-patient isolates for MAB and MMAS . Thus, a conservative threshold of 15 SNPs was chosen 
to define genetic clusters between patients, re presenting likely transmission events or shared 
source acquisition. 
 
Findings : Unpublished data from the CO-RDP of 114 is olates from CF MAB patients across the 
country demonstrates 26 of 114 (23%) had isolates in highly related clusters. Twelve of 114 (11%) 
had isolates in clusters and received care in  the same Center. Clusters are occurring among 
multiple M. abscessus subspecies as well as Mycobacterium avium complex (MAC) subspecies . 
 
Preliminary results from one Care Center utilizin g the HALT NTM toolkit inve stigated six clusters 
of patients with highly similar re spiratory NTM is olates, including M. abscessus and MAC. The 
size of the highly related clusters ranged from 2-3 patients. Among the six identified NTM clusters, 
two clusters occurred wi th MAB, one with MMAS , two with M. avium (MAV) , and one with M. 
intracellulare. No patients within a cluster are related or liv ing together. This is the first description 
of a MAC cluster. 
 
Cluster 1 consisted of 3 subjects with highly related MAV. Subject A was defined as the patient 
with the longest period with MAV+ culture. Subject B was defined as the pa tient with the second 
longest period with MAV+ culture. Subject C was defined as the patient with the shortest period 
with MAV+ culture. Subjects in Cluster 1 were compared using the following pair comparison: 
AB, AC, and BC. The abstraction timeframe for Pair AB was 67 months, Pair BC was 36 months, 
and Pair AC was 79 months. Results of the HA LT NTM toolkit revealed Subjects A and B had a 
1-day CF clinic overlap ( Figure 5 ). At that time, Subject A cultured positive for MAV, but Subject 
B did not. Local clinic IP&C standards at that ti me required patients to d on a mask when outside 
of a clinic room and required gown and gloving by physicians, but not ancill ary staff. Subjects A 
and B were seen by different phys icians and different PFT technici ans. Points of overlap during 
the clinic visit included: Subjects A and B had a clinic visit on the sa me afternoon, waited in a 
shared waiting room, underwent spirometry in  a common access PFT laboratory room, and had a 
nutrition consult within the subjec t’s clinic room with the same  nutritionist. Subject B cultured 
positive for MAV 25 months after the Subject AB overlap. Subjects B and C had a 1-day overlap 
in the clinic 43 days after Subject B first culture d positive for MAV. Points of overlap included: 
Subjects B and C were seen by the same nutritionist  on the same afternoon in CF clinic as well as 
waiting in a shared waiting room , and spirometry in a common access PFT laboratory room prior 
to being placed in their respective clinic room. Subject C first cultured positive for MAV 12 months 
after the Subject BC overlap. Th ere was no overlap among any of the Cluster 1 subjects in the 
hospital setting. 
Cluster 2 consisted of 2 subjects with highly related MAB. Subject A was defined as the  patient 
with the longest period with MAB+ culture. Subject B had the shortest peri od with MAB+ culture. 
The abstraction timeframe for Pair AB was 81 m onths. Results of the HALT NTM toolkit revealed 
Subjects A and B had a 15-day hospitalization over lap. Subject A first cu ltured positive for MAB 
9 days into the 22-day admission wh en overlap occurred. Subject B 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 14 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
 
Figure 5 : Timeline of overlaps observed in Clusters 
1, 2, and 6.  
cultured positive for MAB 14 days into the 16-day admission and 4 days after Subject A. Local 
hospital IP&C standards at that time required patie nts to don a mask when outside of a clinic room 
and required gown and gloving by all staff entering the subject’s  room. Subjects A and B were 
physically separated by one hospital room. At th at time, CF patients had privileges to walk 
unaccompanied through the hospital while donning a mask and had access to a common 
coffeemaker (Keurig) and sink. 
 
Cluster 3 consisted of 2 subjects with highly re lated MAB. Abstraction timeframe was 42 
months. Cluster 4 consisted of 2 subjects with highly  related MMAS. Abstraction was 28 
months. Cluster 5 consisted of 2 subjects with highly related M. intracellulare. Abstraction was 
29 months. Subjects were paired as previously  defined. Results of the HALT NTM toolkit 
revealed there was no overlap identified among subject s in Clusters3, 4, or 5 in the CF clinic or 
hospital setting. 
 
Cluster 6 consisted of 2 subjects with 
highly related MAV . Subjects were 
paired as previously defined. The 
abstraction timeframe for Pair AB was 
45 months. The HALT NTM toolkit revealed Subjects A and B had one 5- day hospitalization overlap. Subject A was 
culture positive for MAV prior to the first 
day of the admission when overlap occurred. Points of overlap included: 
Subjects A and B both had spirometry 
and a physical therapy consult on the same day during the admission overlap. 
Local hospital IP&C standards at that 
time required patients 
to don a mask when outside of a clinic room and required gown and gloving by all staff entering 
the subject’s room. CF patients had privileges to walk unaccompanied through the hospital while 
donning a mask and had access to a common coffeemak er (Keurig) and sink. Subject B cultured 
positive for MAV 21 months after the Subject AB hospitalization overlap . There was no overlap 
among the Cluster 6 subjects in the clinic setting. The timeline of overlap for Clusters 1, 2, and 6 
are shown ( Figure 5 ). 
 
Four sets of paired control patients with MAB were also compared utilizing the HALT NTM 
toolkit. Control patients were iden tified as having isolates that we re determined to be unique and 
unrelated. In all 4 control patient pairs with unr elated strains no healthcare-associated points of 
overlap were identified. The abstraction timeframe  for the control pairs ranged from 4-7 years. 
 
Discussion: Martiniano et. al . evaluated the clinical significance of a first positive CF NTM culture 
and reported subjects that develop active NTM disease have a lower baseline forced expiratory 
volume in 1 second (FEV 1) at the time of first positive culture and an increased rate of decline in 
FEV 1 one year preceding the first positive culture.36 The finding of accelerated lung function 
decline in patients with NTM disease before the time of first positive cu lture strongly suggests 
the presence of respiratory NTM in CF patients for a year or more be fore initial clinical 
detection. Based on that knowledge, the timeline for biol ogically plausible acquisition prior to 
detection is reasonably estimated to be 1-2 years. For this reason, the abstraction timeframe in the 
HALT NTM toolkit timeframe begins 2 years prior to the first positiv e culture of the patient with 
the longest period of time with NTM+ culture. The timeframe ends when the second paired patient 
has a first positive culture. This approach to setting the timeline for data 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 15 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
abstraction ensures plausible direct ionality of transmission and allows  for a 1-2 year timespan from 
NTM acquisition to NTM culture positivity. 
Cluster 1 suggests the possibility of indirect patie nt-to-patient transmission of MAV from Subject 
A to Subject B , with Subject B becoming culture positive for the same highly related strain 25 
months later. Forty-three days after Subject B became culture positive, there was a clinic overlap 
with Subject C. Twelve months  after the BC clinic overlap, Subject C became culture positive for 
the same highly related MAV as Subjects A and B. In this cluster, we ob served a possible instance 
of indirect patient-to-patient co ntact involving the PFT laboratory an d/or a single nutritionist, not 
donning gown and gloves, in both Pairs AB as we ll as BC. Based on the most recent CF IP&C 
guidelines, a plausible bacter ial transmission event may occur with horizontal surface 
contamination of equipment such as in the PFT  laboratory and/or involve surface contamination 
of staff skin and clothing wh en not donning protective, remova ble gowns and gloves while caring 
for CF patients.26 There is no evidence to support healthy carrier status as a source of NTM 
transmission. We hypothesize that transm ission may have occurred via droplets carried on the 
exposed skin or clothing of staff caring for multiple CF patients or by common equipment that 
is used among multiple CF patients . In Cluster 2 , both subjects became MAB+ within 4 days of 
each other during a 15-day hospitalization overla p. Based on  the rapid succession of newly 
positive respiratory MAB cultures among two patients during hospitalization, this cluster appears 
to be a possible candidate for environmenta l healthcare- associated infection . Both subjects were 
exposed to the same environment and resided w ithin a one room distance from each other. 
Determining if the clinical NTM strains are rela ted to the strains isolated from water biofilm 
sources in the hospital would more definitively link the origin of NTM acquisition within the 
healthcare setting. This cluster demonstrates the need fo r simultaneous environmental sampling 
of the healthcare environment as planned in Aim 2. Cluster 6 suggests possible indirect patient-
to-patient transmission of MAV via droplets ca rried on common equipment or shared patient 
resources such as the coffee maker or sink. With standard precautions of gown and glove 
requirement for all staff entering a patient room during hospitaliza tion, indirect transmission of 
droplets carried by contaminated skin or clothing of  staff is less likely since all protective barriers 
are removed prior to leaving a patient room. Co mmon acquisition of a highly related strain from 
the environment also seems unlikely given Subject  A was MAV culture positive prior to hospital 
admission. Clusters 3-5 did not identify any healthcare -associated subject overlap. 
In this study, we are unable to exclude NTM acquisi tion from direct patient- to-patient contact or 
via a common environmental source outside the h ealthcare setting. Evalua tion of non-healthcare 
settings is beyond the scope of this project, but se rves as a potential future  area of inve stigation. 
There may also be a baseline frequency of patient ove rlap that is not related to transmission events 
in the healthcare setting that we expect to capture with evaluati on of control pair s of subjects. 
Despite this small sample size, this preliminary da ta provides insight into the frequency and nature 
of patient overlap in the health care setting and reveals that among CF patients receiving healthcare 
in the same location, there are opportunities for close direct or indirect cont act. In the setting of 
strict IP&C measures with single patient room s, healthcare staff gown ing and gloving, patients 
wearing masks, aggressive cleaning procedures between patients, and maintenance of patient-to-
patient separation of 6 feet or more, direct an d indirect patient overlap should be minimized. 
However, incidental or unanticipated contacts rema in a risk. If patients in fact have no direct or 
indirect contact, investigation of the healthcare environm ent is essential to  eliminate a common 
healthcare-associated environmental source as the point of CF patient NTM acquisition. 
 
2 STUDY RATIONALE 
Reports concerning for direct or  indirect healthcare-associated  NTM transmission continue to 
appear in the literature.8-10 A standardized approach to investigation of healthcare-associated 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 16 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
 
  
 
 
 
 
  
 
    
 
 
  
NTM acquisition in CF patients is critical to prevention . Collecting data on pot ential healthcare- 
associated transmission events in a systematic, uni form format will increase the likelihood of being 
able to create a statistical model to predict in stances of increased probability of transmission 
events. Understanding risk for NTM transmission in the setting of the cu rrent  IP&C guidelines 
has the potential to significantly decrease risk of health care-associated transmission events of 
NTM among people with CF . 
 
An overview of the HALT NTM investigation process is outlined ( Figure 4 ). NJH IRB approval 
for the HALT NTM toolkit is active. Currently th e CO-RDP receives CF NT M respiratory samples 
from across the country and performs culture and WGS analysis. Submitting physicians receive a 
letter acknowledging receipt of the sample; most  commonly informing them that the isolate is 
genetically unique. However, samples initially identif ied as unique may subsequently be identified 
as part of a cluster of highly similar isolates wh en additional strains are added to the database. We 
will continue to update the Care Centers on the st atus of their isolates periodically. When WGS 
related clusters are identified, we will determine if the patients receive care in the same CF Program. 
 
 
 
  
 
 
 
  
 
 
 
 
1) Related clusters are defined as WGS 
SNP distance ≤ 15 AND within a 
Care Center.  
2) Toolkit establishes directionality of 
possible infection transmission based on length of NTM colonization.
 
3) Example pairing of four subjects 
A,B,C,D, where A is the subject with 
the longest NTM colonization: Pair 
AB, AC, AD, BC, BD, CD.  
4) Consults include ENT, respiratory 
therapy, physical therapy, etc.  
 
Figure 4 : HALT NTM Study Flowchart. 
 
When highly similar isolates are identified within an  individual Care Center, a form letter entitled, 
CO-RDP NTM Isolate Results for CF Care Centers ( Appendix 1 ), will be sent to each affected 
institution. The letter informs the Centers of highly similar NTM isolates among two or more 
patients within their Center. The letter will also extend the invitation to participate in the HALT NTM study. To put the study in context, we will pr ovide a summary of clus ter data available to 
date, the goals and methods of this study, as we ll as IRB documents. The invitation to participate 
in HALT NTM will initiate a simple enrollment  process and recommend collaboration with the 
Center’s local IP&C team for investigation into a potential healthcare- associated transmission 
event. With enrollment, instructions will be provided on how to access the web-based HALT NTM 
investigation toolkit to facilita te a standardized healthcare-associated NTM investigation and a 
HALT NTM Toolkit User’s Guide will be provided ( Appendix 2 ). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 17 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
The primary function of the HALT NT M abstraction toolkit is to assess an occurrence of overlap 
between two or more patients identified in the clus ter within the CF healthcare setting, defined as 
CF clinic, hospital and research settings. An overl ap is defined as a healthcare setting where two 
or more CF patients identified in the cluster rece ived care in the same setting for any period of 
time within 24 hours . A point instance of overlap is define d as a specific physical room within 
the healthcare setting (clinic, hos pital, or research area) where tw o or more CF patients identified 
in the cluster received care. An example includes  the following: Subject 1 and Subject 2 are both 
seen in clinic on 12/12/16. Subject 1 is in the clinic from 10:00-12: 00. Subject 2 is in  clinic from 
1:00-3:00. In this example, an overlap in clin ic is observed between Subject 1 and Subject 2 
because two clustered patients attended the same CF clinic on the same day. During this example 
visit, Subject 1 performs spirometry in PFT laboratory Room 1 at 10:00 on 12/12/16 and Subject 
2 performs spirometry in PFT laboratory Room 1 at 2:00 on 12/12/16. In this example, a point 
instance overlap is observed in the PFT laboratory because two clustered patients were in Room 1 
in the PFT laboratory on the same day. Because pot ential transmission events can be direct or 
indirect, an overlap does not have  to occur at the exact same ti me on a given day. Additionally, 
subjects may be observed to have an overlap, but a point instance of overlap may not be identified. 
In either case, data will be recorded accordingly. 
 
Testing for water biofilm sources in the CF  healthcare setting: NTM are known to colonize 
municipal water systems and have been identified in healthcare facilities.27-29 NTM are found in 
free flowing water as well as biof ilms on water supply system pipes and both have been implicated 
in nosocomial outbr eaks of infection.30 Modes of acquisition and tr ansmission of NTM among CF 
patients remains unclear. A multicenter preval ence study of NTM in 2003 did not implicate 
nosocomial transmission among CF patients, and mol ecular analysis at that time revealed almost 
all patients had unique NTM strains.31 A more recent study descri bed a biphasic nosocomial 
outbreak of MAB linked to hospital tap water.32 The authors attributed the first phase of the 
outbreak of respiratory MAB to routine care prac tices using hospital tap water with exposure to 
the aerodigestive tract in high-risk patients. Th e second phase outbreak occurred among cardiac 
surgery patients with invasive MAB infections a nd was attributed to contaminated heater-cooler 
units of cardiopulmonary bypass machines. Others have implicated inhala tion of aerosolized NTM 
via showerheads as a possible sour ce of acquisition of infection.33 A recent study demonstrated 
that showerheads receiving water from  municipal water treatment plants harbor clinically-
relevant NTM .34 On a more global level, Bryant et al. reported widespread dominant circulating 
NTM clones.11 This worldwide distributi on could be explained by prevalent environmental 
genotypes . Further environmental evaluation of healthcare environments is essential to 
understanding healthcare- associated environmental risk factors in acquisition of NTM infection . 
 
Biofilms are the preferred samples for isolation of  NTM in water systems of all types because the 
hydrophobic NTM cells preferentially adhere to pipe  surfaces where they form biofilms, thus 
ensuring their persistence.  Average colony counts/cm2 of premise plumbing biofilm samples is 
between 1,000-15,000 CFU/cm2, whereas water (suspended) densities are between 10-100 
CFU/mL.35 Thus, the sensitivity of NTM detection is orders of magnitude higher for biofilm 
compared to water samples. With advanced molecular analys is and better understanding of 
previous NTM nosocomial outbreaks, the CO-RDP findings of highly relate d NTM clusters among 
CF patients within the same CF Care Centers raises concern for nosocomial 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 18 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
transmission . In order to better unde rstand risk for nosocomial NTM acquisition among CF 
patients with clonal NTM respiratory isolates, determining the relatedness of clustered CF NTM 
clinical respiratory isolates to environmental water sources in the CF healthcare setting is 
imperative . 
 
2.1 Risk / Benefit Assessment 
As a retrospective, epidemiologic study there is no anticipated direct benefit to participants. There 
is minimal risk to subjects in the study. 
 
3 STUDY OBJECTIVES 
 
3.1 Primary Objective 
PART A / Epidemiologic Investigation: 
The primary objective of the epidemiologic investigation is to facilitate implementation of a 
stepwise process by which indivi dual Centers perform retrospectiv e epidemiologic evaluation of 
patients identified by the CO-RDP as part of an NTM cluster. 
 
PART B / Water Biofilm Collection: 
The primary objective of water biofilm collection is to determine of NTM strains identified in 
clusters are related to the strains isolated from wa ter biofilm sources in the CF healthcare setting. 
3.2 Secondary Objectives 
PART A / Epidemiologic Investigation: 
The secondary objectives are to: 
 Determine subject overlap: 
Frequency, location and source of overlap within  the healthcare system  within the 2-year 
abstraction timeframe. 
 Evaluate infection prevention and control (IP&C) measures: 
Use of single patient rooms, healthcare sta ff gowning and gloving, pati ents wearing masks, 
aggressive cleaning procedures between patient s, and maintenance of  patient-to- patient 
separation of 6 feet or more within  the 2-year abstraction timeframe. 
 
PART B / Water Biofilm Collection: 
The secondary objectives are to: 
 Culture healthcare-associated wa ter biofilm environmental NTM. 
 Evaluate effectiveness of a standardized NT M disease treatment protocol to serve as 
baseline/reference estimates of endpoints in cl inical care and future  therapeutic trials. 
 Support biomarker development for markers of  NTM treatment response through banking 
of clinical specimens and NTM is olates linked with outcomes data. 
 Characterize clinical features of patients achieving treatment success compared to those 
unresponsive to treatment. 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 19 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
4 STUDY DESIGN 
 
4.1 Study Overview 
PART A / Epidemiologic Investigation: 
This study will retrospectively revi ew and collect data from patients with CF and culture positive 
for an NTM isolate falling in a highly-related clus ter, identified by the CO-RDP, within a single 
CF Care Center. Two control subjects will be identified by the CO-RDP for every subject falling 
within a cluster. Retros pective epidemiologic data  collection and i nput into REDCap is detailed 
(Appendix 1 and 2) . Up to 20 Care Centers will be offered enrollment. 
 
PART B / Water Biofilm Collection : 
This study will also collect and analyze water bi ofilms from a variety of water sources in the 
healthcare setting including sink  faucets, showerheads, shower  hoses, ice machines, drinking 
fountains, and decorative water features. Envir onmental sampling instructions are detailed 
(Appendix 3) . 
 
5 CRITERIA FOR EVALUATION 
 
5.1 Primary Endpoint 
PART A / Epidemiologic Investigation: 
Identification of a shared healthcare-associated s ource(s) between patients in a Care Center with 
identical NTM isolates. 
 
PART B / Water Biofilm Collection: 
Identification of clinically-relevant NTM isolates  and prevalent environmental genotypes with in 
healthcare setting water biofilms. 
 
5.2 Secondary Endpoints 
PART A / Epidemiologic Investigation: 
The secondary endpoints are: 
 Adherence to CF IP&C guidelines. 
 Characterization of points of patient overlap. 
 
PART B / Water Biofilm Collection: 
The secondary endpoints are: 
 Incidence and prevalence of NTM species/subs pecies within healthcare water biofilms. 
 Determine if biofilm isolates are highly re lated to isolates reco vered from patients. 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 20 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
6 PARTICIPANT SELECTION 
 
6.1 Study Population 
Participants with a diagnosis of CF who meet all of the inclusion and none of the exclusion criteria 
will be eligible for participation in this study. 
 
6.2 Inclusion Criteria 
PART A / Epidemiologic Investigation: 
1. Male or female participant of any age at enro llment Diagnosis of CF consistent with the 2017 
CFF Guidelines. 
2. NTM-positive for a species or sub-species in the 2 years prior to enrollment that has never 
been treated or current Denver si ngle-center stud y participant. 
 
PART B / Water Biofilm Collection: 
N/A 
 
6.3 Exclusion Criteria 
PART A / Epidemiologic Investigation: 
N/A 
 
PART B / Water Biofilm Collection: 
N/A 
 
6.4 Study Specific Tolerance for Inclusion/Exclusion Criteria 
N/A 
 
6.5 Screen Fail Criteria 
N/A 
 
7 CONCURRENT MEDICATIONS 
 
7.1 Allowed Medications and Treatments 
No available therapy for CF is restricted. 
 
7.2 Prohibited Medications and Treatments 
N/A 
 
8 STUDY TREATMENTS 
Part A (Epidemiologic Investigatio n) is retrospective collection of epidemiologic data. Part B 
(Water Biofilm Collection) is exclusively envi ronmental sampling and does not include subject 
involvement. 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 21 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
9 STUDY PROCEDURES AND GUIDELINES 
REDCap data collection is deta iled (Appendix 1 and Appendix 2 - Epidemiologic Investigation). 
Environmental sampling instructi ons are detailed (Appendix 3). 
9.1 Clinical Assessments 
 
9.1.1 Demographics and CFF Registry ID 
Demographic information (date of birth, sex, ra ce, zip code) will be recorded. CFF Registry 
number will be recorded for pa rticipating CF participants. 
9.1.2 CF Diagnosis 
CF diagnosis will be confirmed by the participating Care Center. 
 
9.1.3 NTM History 
Results from molecular analysis performed at  National Jewish Health Mycobacteriology and 
Pharmacokinetics Laboratory will be recorded. 
 
9.1.4 NTM Disease Diagnosis Evaluation 
Investigators will record if a diagnosis of CF  NTM disease is met based on the US CFF and 
European CF Society consensus recommendations for the management of NTM in individuals 
with CF. 
 
9.1.5 NTM Treatment 
Investigators will record if the subject underwent or is undergoing treatment of CF NTM disease. 
 
9.1.6 Drug Toxicity Monitoring 
N/A 
 
9.2 Clinical Laboratory Measurements 
N/A 
 
9.3 Research Laboratory Measurements 
N/A 
 
10 EVALUATIONS BY VISIT 
Not applicable. 
 
11 ADVERSE EXPERIENCE REPO RTING AND DOCUMENTATION 
Not applicable. Adverse Events an d Serious Adverse Experience wi ll not be reported for this 
retrospective study. 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 22 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
12 DISCONTINUATION AND REPLACEMENT OF PARTICIPANTS 
 
12.1 Early Withdrawal of Participants from the Study 
N/A. 
 
12.2 Replacement of Participants 
N/A 
 
13 PROTOCOL VIOLATIONS 
A protocol violation occurs when the participant, investigator, or the Sponsor fails to adhere to 
significant protocol requirements affecting the eligibility criteria  and primary endpoint criteria. 
Failure to comply with Good Clinical Practice (G CP) guidelines may also result in a protocol 
violation. 
There will be no protocol violations. We will mon itor for protocol deviations. If deviations are 
identified, we will request modifications as  necessary to meet protocol guidelines. 
 
14 DATA SAFETY MONITORING 
N/A 
 
15 STATISTICAL METHODS AND CONSIDERATIONS 
 
15.1 General Considerations 
For each of the primary and secondary outcomes, bios tatistical analysis of the multicenter data will 
be completed using both qualitative and quantitativ e approaches. We will identify a set of variables 
used to assess degree of proximity of subjects in  time and/or space. For example, two subjects with 
neighboring rooms at a hospital would have close proximity, but proximity would be increased for 
two subjects at a facility that had longer overlap time , relative to a pair of subjects that had shorter 
overlap. We will explore creating composite measures of quantitative proximity that incorporate multiple variables. Qualitative measures of proxim ity, such as  location type (testing laboratory, 
patient room) will also be assessed. Several testing approaches will be used to compare the relationship between similarity of strains and degree of proximity of subjects. In the simplest form, 
descriptive statistics will be computed for proxi mity variables, for pairs of subjects who are 
determined to have similar strains versus those who have dissimilar strain s, and multivariate or 2-
sample t-tests will be performed to test for differences between these groups. More advanced 
modeling will be performed to determine the rela tionship between the degree of similarity in 
strains with the proximity and subject characteristic variables; multiple linear regression will be used when considering continuous strain similarit y, while multiple logistic regression will be used 
when considering subjects with dichotomized (similar/dissimilar) strains to other subjects. 
 
15.1.1  Data Sets Analyzed 
All analyses will be based on the group of subjects  that are identified by the CO-RDP as having 
NTM isolates, defined as highly si milar strains at the genomic le vel, harbored by two or more 
patients within a si ngle Care Center. 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 23 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
15.2 Demographic and Baseli ne Characteristics 
The following baseline demographic and clinical char acteristics will be reported: age, gender, race, 
ethnicity, zip code, and NTM sub/species. 
15.3 Analysis of Primary Endpoint 
PART A / Epidemiologic Investigation: 
The primary endpoint will characterize the origins and prevalence of healthcare-associated patient-
to-patient transmission of NTM among different CF Care Centers. We will further characterize the source(s) of direct or indirect transmission of NTM within an indi vidual CF healthcare setting. We 
will identify a set of variables used to assess degree of proximity of subjects in time and/or space. For example, two subjects with neighboring room s at a hospital would have close proximity, but 
proximity would be increased for two subjects at a facility that had longer overlap time, relative to 
a pair of subjects that had shorter overlap. We will explore creating composite measures of quantitative proximity that incorporate multiple vari ables. Qualitative measures of proximity, such 
as location type (testing laboratory, patient room) will also be assessed. Several testing approaches 
will be used to compare the relationship between similarity of strains and degree of proximity of subjects. In the simplest form, de scriptive statistics will be comput ed for proximity variables, for 
pairs of subjects who are determined to have si milar strains versus those who have dissimilar 
strains, and multivariate or 2-sample t-tests will be performed to test for differences between these 
groups. More advanced modeling will be performe d to determine the relationship between the 
degree of similarity in strains with the proximity and subject characteristic variables; multiple linear regression will be used when considering continuous strain sim ilarity, while multiple logistic 
regression will be used when considering subjects  with dichotomized (similar/dissimilar) strains 
to other subjects. 
PART B / Water Biofilm Collection: 
The primary endpoint will charac terize clinically-relevant NTM found in water biofilms within 
CF healthcare settings and determine if the biofilm isolates are highly related to isolates recovered from patients. 
15.4 Analysis of Secondary Endpoints 
PART A / Epidemiologic Investigation: 
The secondary endpoints will characterize CF Center  adherence to the CF IP&C guidelines as well 
as characterize points of patient overlap. Basic summaries of points of potential transmission 
overlap will be provided. 
 
PART B / Water Biofilm Collection: 
The incidence and prevalence of NTM species a nd subspecies within healthcare water biofilms 
will be characterized. Comparisons of NTM biofilm isolates and highly related patient isolates will be provided. 
 
15.5 Interim Analysis 
No formal interim analysis involving a data monitoring committee (DMC) is planned. However, 
annual reports summarizing key variables related to  site enrollment and adherence to protocol 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 24 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
will be generated. These reports will help guide prot ocol revisions. Details of the planned analysis 
for these annual reports can be found in the Statistical Analysis Plan (SAP). 
 
15.6 Sample Size 
Up to 20 CF Care Centers are eligible for enroll ment. Sample size will be determined based on 
CO-RDP WGS finding of highly re lated NTM species and subspecies among patients receiving 
care at an individual CF Care Center. 
 
16 DATA COLLECTION, RETENTION AND CLINICAL MONITORING 
 
16.1 Data Collection Instruments 
Study personnel at each site will enter data from  the electronic medical record and CF Registry 
corresponding to a participant’s visit into the prot ocol-specific electronic REDCap database when 
the information corresponding to that visit is available. Participants will not be identified by name in the study database to be collected by the Sponsor  (or designee), but will be identified by a site 
number, participant number and initials. 
For all REDCap data colle ction, the time and date stamp trac ks the person entering or updating 
data and creates an electronic audit trail. 
The Investigator is responsible for all information collected on participants enrolled in this study. 
All data collected during the course of this study must be revi ewed and verified for completeness 
and accuracy by the Investigator. At the completion of the study, a copy of the REDCap data  will 
be provided to the site to be reta ined at the Investigator’s site. 
The data may be monitored by the CFF at any time during the study. 
 
16.2 Data Management Procedures 
The National Jewish Health Research Informatics Se rvices Core will be used as a central location 
for data processing and management. REDCap, a software toolset and workflow methodology for 
electronic collection and management of resear ch and clinical trial data, was developed by 
Vanderbilt University, with collaboration from a consortium of institutional partners. REDCap 
data collection projects rely on a thorough study-specific data dicti onary defined in an iterative 
self-documenting process by all members of the re search team with planning assistance from the 
Research Informatics Services Core. The iterative development and testing process results in a well-planned data collection strate gy for individual studies. REDC ap servers are housed in a local 
data center at National Jewish Health and all web-based information transmission is encrypted. 
REDCap was developed specifica lly around HIPAA-security guide lines and is recommended to 
National Jewish Health research ers by both our Privacy Office and Institutional Review Board. 
REDCap currently supports 240+ academic/non-pr ofit consortium partners on six continents and 
over 26,000 research end-users (www.project- redcap.org). 
Data Quality Control and Reporting 
After data have been entered into the study data base, data validation checks will be applied on a 
regular basis. As part of data  analysis, Matthew Stra nd, the lead biostatis tician on the study, will 
monitor for data outliers and will perform data cont rol. If data entry errors are encountered, the 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 25 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
study database will be updated in accordance with the resolved queries. All changes to the study 
database will be documented in an audit trail. 
 
16.3 Security and Archival of Data 
REDCap is a secure, web-based application designed  to support data capture  for research studies. 
REDCap is maintained by the REDCap Consortium  which is comprised of over 3,500 institutional 
partners including National Jewi sh Health, and is administrate d locally by the National Jewish 
Health Research Informatics Services. 
REDCap utilizes as suite of features that s upport HIPAA compliance. Access to the database 
requires user authentication with password. Data is  accessed based on  the individual’s role on the 
project. Logging and audit trails are maintained on all data interactions. All data is stored on a 
secure server, and backups are encrypted. Automatic  backup of the server s are performed  twice 
daily. 
 
16.4 Availability and Retention of Investigational Records 
The Investigator must make study data accessible to the monitor, other authorized  representatives 
of the Sponsor (or designee), IRB/IEC, and Regulatory Agency (e.g., FDA) inspectors upon 
request. Hard copy files will not be created. 
All study information will be maintained in REDCap  for a period of 5 years after database lock. 
There may be other circumstances for which the Spons or is required to main tain study records and, 
therefore, the Sponsor should be contacted prior to removing study records for any reason. 
 
16.5 Monitoring 
The study PIs and the CFF are authorized to m onitor the study. By signing this protocol, the 
Investigator grants permission to  the Sponsor (or designee), and a ppropriate regulatory authorities 
to conduct on-site monitoring and/or auditing of all appropriate study documentation. Monitoring visits will be conducted by representatives of th e Sponsor according to the U.S. CFR 21 Part 312 
and ICH Guidelines for GCP (E6) and to ensure  investigator compliance to 21 CFR Parts 50, 56 
and 312 and to GCP. 
 
16.6 Participant Confidentiality 
In order to maintain participant confidentialit y, only a site number, participant number and 
participant initials will identify all study participants in REDCa p. The participant’s CFF patient 
registry number will also be collected. Additiona l participant confidentiality issues (if applicable) 
are covered in the Clin ical Study Agreement. 
 
17 ADMINISTRATIVE, ETHICAL, REGULATORY CONSIDERATIONS 
The study will be conducted according to the D eclaration of Helsinki, Protection of Human 
Volunteers (21 CFR 50), Institutional Review Boar ds (21 CFR 56), and Oblig ations of Clinical 
Investigators (21 CFR 312). 
To maintain confidentiality, all laboratory specime ns, evaluation forms, reports and other records 
will be identified by a coded number and initials only. Clinical information will not be released 
without written permission of the participant, except as necessary for monitoring by the FDA. 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 26 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
The Investigator must also comply with all appl icable privacy regulation s (e.g., Health Insurance 
Portability and Accountability Act of 1996, EU Data Protection Directive 95/46/EC). 
 
17.1 Protocol Amendments 
Any amendment to the protocol will be written by the Sponsor. Protocol amendments cannot be 
implemented without prior written IRB/IEC approva l except as necessary to eliminate immediate 
safety hazards to participants. A protocol amendment intended to eliminate an apparent immediate hazard to participants may be implemented immedi ately, provided the IRBs are notified within 5 
working days. 
 
17.2 Institutional Review Boards and Independent Ethics Committees 
The protocol and consent form will be reviewed and approved by the IRB/IEC of each participating 
center prior to study initia tion. Serious adverse experi ences regardless of causa lity will be reported 
to the IRB/IEC in accordance with the standard ope rating procedures and policies of the IRB/IEC, 
and the Investigator will keep the IRB/IEC informed as to the progress of the study. The Investigator will obtain assurance of IRB/IEC compliance with regulations. 
Any documents that the IRB/IEC may need to fulfill its responsibilities (such as protocol, protocol 
amendments, Investigator’s Brochure, consent forms, information concerning participant 
recruitment, payment or compensation procedures, or other pertinent information) will be submitted to the IRB/IEC. The IRB/IECs written unconditional approval of the study protocol and 
the informed consent form will be in the possession of the Investigator before the study is initiated. 
The IRB/IEC’s unconditional approval statement w ill be transmitted by the Investigator to the 
Sponsor or designee prior to the sh ipment of study supplies to the si te. This approval must refer to 
the study by exact protocol title and number and should identify the documents reviewed and the 
date of review. 
Protocol and/or informed consent modifications or changes may not be initiated without prior 
written IRB/IEC approval except when necessa ry to eliminate immediate hazards to the 
participants or when the change (s) involves only logistical or ad ministrative aspects of the study. 
Such modifications will be submitted to the IRB/IE C and written verification that the modification 
was submitted and subsequently approved should be obtained. 
The IRB/IEC must be informed of revisions to other documents originally submitted for review; 
serious and/or unexpected adverse experiences o ccurring during the study in accordance with the 
standard operating procedures and policies of the IRB; new information that  may affect adversely 
the safety of the participants of the conduct of the st udy; an annual update an d/or request for re-
approval; and when the study has been completed. 
 
17.3 Informed Consent Form 
N/A 
 
17.4 Consent for Collection and Use of CFF Registry ID Number 
To facilitate possible future evaluation of retr ospective and prospective information from all 
participants in this study, the participant’s CFF Registry ID number will  be collected. The CFF 
registry collects data on all CF pa tients who consented to particip ate in the CFF registry and who 
are followed at CFF-accredited care centers. The regi stry data includes information from clinical 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 27 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
encounters, hospitalizations courses of antibioti cs, and year-end surveys.  Data also include 
microbiology results, spirometry results, CF genotype  and other information. If specific consent is 
given to collect this number, the participant’s CF  registry number will be recorded in the CRF. 
 
17.5 Publications 
The preparation and submittal for publication of manuscripts contai ning the study results shall be 
in accordance with a process determined by mutual written agreement among the study Sponsor 
and participating institutions. The publication or presentation of any study results shall comply with all applicable privacy laws, including, but not  limited to, the Health Insurance Portability and 
Accountability Act of 1996. 
 
17.6 Investigator Responsibilities 
By signing the Agreement of Investigator  form, the Investigator agrees to: 
1. Conduct the study in accordance with the protoc ol and only make changes after notifying the 
Sponsor (or designee), except when to protect th e safety, rights or we lfare of participants. 
2. Personally conduct or supervise the study (or investigation). 
3. Ensure that the requirements relating to obtaining informed consent and IRB review and 
approval meet federal guidelines, as st ated in § 21 CFR, parts 50 and 56. 
4. Ensure that all associates, colleagues and empl oyees assisting in the conduct of the study are 
informed about their obligations in meeting the above commitments. 
5. Maintain adequate and accurate  records in accordan ce with §21 CFR 312.62 and to make those 
records available for inspection wi th the Sponsor (or designee). 
6. Ensure that an IRB that complies with the requir ements of §21 CFR part 56 will be responsible 
for initial and continuing review and approval of the clinical study. 
7. Promptly report to the IRB and the Sponsor (or designee) all ch anges in the research activity 
and all unanticipated problems involving risks to participants or others (to include amendments 
and IND safety reports). 
8. Seek IRB approval before any changes are made in the research study, except when necessary 
to eliminate hazards to the participants. 
9. Comply with all other requirement s regarding the obligat ions of clinical investigators and all 
other pertinent requirements listed in § 21 CFR part 312. 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 28 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
 
18 REFERENCES 
 
1. Qvist T, Pressler T, Hoiby N, Katzenst ein TL. Shifting paradigms of nontuberculous 
mycobacteria in cystic fi brosis. Respir Res 2014;15:41. 
2. Floto RA, Olivier KN, Saiman L, et al. US Cy stic Fibrosis Foundation and European Cystic 
Fibrosis Society consensus recommendations  for the management of non-tuberculous 
mycobacteria in individuals with cyst ic fibrosis. Thorax 2016;71 Suppl 1:i1-22. 
3. Adjemian J, Olivier KN, Prevots DR. Ep idemiology of Pulmonary Nontuberculous 
Mycobacterial Sputum Positivity in Patients with  Cystic Fibrosis in the United States, 2010- 
2014. Ann Am Thorac Soc 2018;15:817-26. 
4. Primm TP, Lucero CA, Falkinham JO, 3rd. Health  impacts of environmental mycobacteria. 
Clin Microbiol Rev 2004;17:98-106. 
5. Falkinham JO, 3rd. Nontuberculous mycobacteria  from household plumbing of patients with 
nontuberculous mycobacteria disease.  Emerg Infect Dis 2011;17:419-24. 
6. Honda JR, Hasan NA, Davidson RM, et al. Envi ronmental Nontuberculous  Mycobacteria in 
the Hawaiian Islands. PLoS Negl Trop Dis 2016;10:e0005068. 
7. Prevots DR, Adjemian J, Fernandez AG, Know les MR, Olivier KN. Environmental risks for 
nontuberculous mycobacteria. Indivi dual exposures and climatic fact ors in the cystic fibrosis 
population. Ann Am Thorac Soc 2014;11:1032-8. 
8. Aitken ML, Limaye A, Pottinger P, et al. Re spiratory outbreak of Mycobacterium abscessus 
subspecies massiliense in a lung transplant and cy stic fibrosis center. Am J Respir Crit Care 
Med 2012;185:231-2. 
9. Bryant JM, Grogono DM, Greaves D,  et al. Whole-genome sequencin g to identify transmission 
of Mycobacterium abscessus betwee n patients with cys tic fibrosis: a retros pective cohort study. 
Lancet 2013;381:1551-60. 
10. Johnston DI, Chisty Z, Gross JE, Park SY. Inve stigation of Mycobacterium abscessus outbreak 
among cystic fibrosis patients, Ha waii 2012. J Hosp Infect 2016;94:198-200. 
11. Bryant JM, Grogono DM, Rodrigu ez-Rincon D, et al. Emergen ce and spread of a human- 
transmissible multidrug-resistant nontuberc ulous mycobacterium. Science 2016;354:751-7. 
12. Colorado Cystic Fibrosis Research & Development Program. National Jewish Health. 
(Accessed Sept 2, 2018, at  https://www.nationaljewish.org/cocfrdp .) 
13. Epperson LE, Hasan NA, Davidson RM, et al. The Colorado Research and Development 
Program Molecular and Genomics Core: Surv eillance for Nontuberculous Mycobacteria 
Transmission or Shared Environmental Exposure in US Cystic Fibrosis Patients. Poster session 
presented at: The 31st Annual North American Cystic Fibrosis Conference; 2017 Nov 2-4; 
Indianapolis, IN. 
14. Healthcare-Associated Infection (HAI) Outbreak  Investigation Toolkit. Centers for Disease 
Control and Prevention, 2013. (Accessed Sept 2, 2018, at  
https://www.cdc.gov/hai/outbr eaks/outbreaktoolkit.html .) 
15. Lipner EM, Knox D, French J, Rudman J, Str ong M, Crooks JL. A Geospatial Epidemiologic 
Analysis of Nontuberculous Mycobacterial Infe ction: An Ecological Study in Colorado. Ann 
Am Thorac Soc 2017;14:1523-32. 
16. Lande L, Alexander DC, Wallace RJ Jr, Kwa it R, Iakhiaeva E, Williams M, et al. 
Mycobacterium avium in community and hous ehold water, suburban Philadelphia, 
Pennsylvania, USA, 2010-2012. Emerg Infect Dis 2019 Mar 14. 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 29 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
17. Cystic Fibrosis Foundation Patient Registry 2016 Annual Data Report. Bethesda, MD: Cystic 
Fibrosis Foundation; 2017. 
18. Cystic Fibrosis Foundation Patient Registry 2017 Annual Data Report. Bethesda, MD: Cystic 
Fibrosis Foundation; 2018. 
19. Hasan NA, Davidson RM, Epperson LE, et al. The Genomic Epidemiology of Mycobacterium 
avium complex vs Mycobacterium abscessus in United States Cystic Fibrosis Patients. Poster 
session presented at: The 31st Annual North American Cystic Fibrosis Conference; 2017 Nov 
2-4; Indianapolis, IN. 
20. Martiniano SL, Davidson RM, Nick JA. Nontube rculous mycobacteria in cystic fibrosis: 
Updates and the path forward. Pediatr Pulmonol 2017;52:S29-S36. 
21. Tortoli E, Kohl TA, Trovato A, et al. Mycobacter ium abscessus in patients with cystic fibrosis: 
low impact of inter-human transmission in Italy. Eur Respir J 2017;50. 
22. Adjemian J, Olivier KN, Seitz AE, Holland SM , Prevots DR. Prevalence of nontuberculous 
mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med 
2012;185:881-6. 
23. Gross JE. Mycobacterium abscessus Epidemic Among Cystic Fibrosis  Patients. Poster session 
presented at: The 27th Annual North American Cystic Fibrosis Conference; 2013 Oct 17-19; 
Salt Lake City, UT. 
24. Gross JE. Overcoming Barriers to Infection Control in Patients With Cystic Fibrosis. Oral 
presentation at: The 28th Annual North American Cystic Fibrosis Conference; 2014 Oct 9- 11; 
Atlanta, GA. 
25. Gross JE. Healthcare-Associated Transmissi on of Nontuberculous mycobacteria Among 
Patients With Cystic Fibrosis. Oral presenta tion at: The 32nd Annual No rth American Cystic 
Fibrosis Conference; 2018 Oct 18-20; Denver, CO. 
26. Saiman L, Siegel JD, LiPuma JJ, et al. Infec tion prevention and contro l guideline for cystic 
fibrosis: 2013 update. Infect Control Hosp Epidemiol 2014;35 Suppl 1:S1-S67. 
27. Williams MM, Armbruster CR, Arduino MJ. Plumbing of hospital premises is a reservoir for 
opportunistically pathogenic microorgani sms: a review. Biofouling 2013;29:147-62. 
28. Shin JH, Lee EJ, Lee HR, et al. Prevalence of non-tuberculous mycoba cteria in a hospital 
environment. J Hosp Infect 2007;65:143-8. 
29. du Moulin GC, Stottmeier KD, Pelletier PA, Tsang AY, Hedley-Whyte J. Concentration of 
Mycobacterium avium by hospital ho t water systems. JAMA 1988;260:1599-601. 
30. Wallace RJ, Jr., Brown BA, Griff ith DE. Nosocomial outbreaks/ pseudo-outbreaks caused by 
nontuberculous mycobacteria. A nnu Rev Microbiol 1998;52:453-90. 
31. Olivier KN, Weber DJ, Wallace RJ, Jr., et al. Nontuberculous mycobacteria. I: multicenter 
prevalence study in cystic fibrosis. Am  J Respir Crit Care Med 2003;167:828-34. 
32. Baker AW, Lewis SS, Alexander BD, et al. Tw o-Phase Hospital-Associated Outbreak of 
Mycobacterium abscessus: I nvestigation and Mitigation. Clin Infect Dis 2017;64:902-11. 
33. Thomson R, Tolson C, Carter R, Coulter C,  Huygens F, Hargreaves M. Isolation of 
nontuberculous mycobacteria (NTM) from house hold water and shower aerosols in patients 
with pulmonary disease caused by NT M. J Clin Microbiol 2013;51:3006-11. 
34. Gebert MJ, Delgado-Baquerizo M, Oliverio AM, et al. Ecological Analyses of Mycobacteria 
in Showerhead Biofilms and Their Rele vance to Human Health. MBio 2018;9. 
35. Falkinham JO, 3rd, Norton CD, LeChevallier  MW. Factors influencing numbers of 
Mycobacterium avium, Mycobacterium intracellu lare, and other Mycob acteria in drinking 
water distribution systems. Appl  Environ Microbiol 2001;67:1225-31. 
 
 
36. Martiniano SL, Sontag MK, Daley CL, Nick JA , Sagel SD. Clinical significance of a first 
positive nontuberculous mycobacteria culture in cystic fibrosis. Ann Am Thorac Soc 2014;11:36-44. 
   
 
APPENDIX 1 COLORADO-RESEARCH AND DE VELOPMENT PROGRAM NTM ISOLATE 
LETTER 
 
 
 
October 30, 2019 
 
Dear Dr. , 
 
The CF Foundation-funded Colorado Research and Deve lopment Program (RDP) is engaged in a nationwide 
study of the genetic characterizatio n of nontuberculous mycobacterium (N TM) across United States CF Care 
Centers. We recently confirmed identifi cation of NTM isolates from the CF patients indicated below, who receive 
care in your CF center. We have genotyped these isolates by using rpoB gene sequencing (clinical only, not for 
research), as well as whole genome sequencing, which pr ovided a genetic profile (DNA fingerprint), enabling us 
to determine similarity between strains. 
 
This analysis indicates that the patients listed below are infected with Mycobacterium abscessus ssp. abscessus 
and share a highly similar strain that  could be due to a shared environm ental exposure or possibly person-to- 
person transmission. 
 
Patient Name Date of Birth 
      
      
      
 
The information above is for resear ch purposes only. If you are interest ed in conducting an independent, 
internal investigation for a shared he althcare-associated source (s) between two or more patients in your Center, 
please contact Jane Gross, MD at GrossJane@njhealth.org to access the Healthcare-Associated Links in 
Transmission of Nontuberculous Myc obacteria in Patients with Cystic  Fibrosis (HALT NTM) toolkit. 
 
If you have questions about th is report please contact the Clinical Research Coordinator, Adrah Levin, MPH, at 
LevinA@njhealth.org or (303) 398-1407. You can also contact the RDP Program Director, Jerry Nick, MD, at 
NickJ@njhealth.org or at (303) 398-1579. If one of more of these patients are no longer under your care, or if 
you believe you have received this le tter in error, please contact us  so we can update our records. 
 
Sincerely, 
 
Charles L Daley, MD 
Director of RDP Culture and Biorepository Core 
Chief of Division of Mycobacterial and Respiratory Infections 
DaleyC@NJHealth.org  
 
 

 
Previously reported patients  sharing similar strains 
 
Mycobacterium abscessus, subsp. abscessus (reported 5/2018) 
Patient Name Date of Birth 
      
      
 
Mycobacterium abscessus, subsp. abscessus (reported 1/2019) 
Patient Name Date of Birth 
      
      
 
Mycobacterium abscessus ssp. massiliense (reported 1/2019) 
Patient Name Date of Birth 
      
      
 
Mycobacterium intracellulare (reported 1/2019) 
Patient Name Date of Birth 
      
      
 
Mycobacterium avium (reported 1/2019) 
Patient Name Date of Birth 
      
      
      
      
 
Mycobacterium abscessus ssp. abscessus (reported 1/2019) 
Patient Name Date of Birth 
      
      
 
Mycobacterium avium (reported 1/2019) 
Patient Name Date of Birth 
      
      
 
Mycobacterium abscessus ssp. abscessus (reported 9/2019) 
Patient Name Date of Birth 
      
      
      
 
 
 
 
Mycobacterium abscessus ssp. abscessus (reported 9/2019) 
Patient Name Date of Birth 
      
      
 
Mycobacterium abscessus ssp. abscessus (reported 9/2019) 
Patient Name Date of Birth 
      
      
      
      
 
Mycobacterium abscessus ssp. abscessus (reported 9/2019) 
Patient Name Date of Birth 
      
      
      
      
 
  
 
  
 
 
 
  
 
  
 
  
 
  
 
  
 
  
 
 
 
 
 

Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 32 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
 
APPENDIX 2 REDCAP USER GUIDE 
So, you’ve received a letter from  National Jewish Health Advanced Diagnostic Laboratories 
(NJH ADx) saying you have patients  at your center with a highly  similar strain of NTM. Now 
what? 
1. Contact Dr. Gross at NJH. She will help you with initial questions regarding study 
design and study start-up, including IRB and database requirements. 
2. For NJH REDCap access, you will be sent a li nk to complete REDCap training. You will 
be asked the following: 
 For the question “Are you an employee of  National Jewish Health?” select No. 
 Explain your affiliation as “HALT NTM” 
 National Jewish Health S ponsor is “Jane Gross” 
 For department, indicate your CF center/institution name. 
 Complete the rest as indicated. 
 Email Dr. Gross or Katie once you’ve been given access so you can be added to 
the project. 
3. Now you have access to the database. Log on to REDCap. On the welcome screen, open 
the HALT NTM project. 
4. On the left hand side under Applications, open the File Repository. Download the HALT 
NTM cheat sheet. 
5. Print a HALT NTM cheat sheet for each unique pair: 
 If there are two patients listed on you r letter, you will have one unique pair. 
 If there are three patients listed on your letter, you will have three unique pairs. 
 If there are four patients listed on your letter, you will have six unique pairs. 
 This is because the date ranges are comp ared between two subjects and is unique 
for each pair. 
6. Complete the first six lines on the HALT NTM cheat sheet for each unique pair. You 
will need to refer to it during pairing and data extraction. 
7. Back in REDCap, on the left hand side under Data Collection, click Add / Edit Records. 
On the Add/Edit Records page, click on the but ton Add new record. You will be taken to 
the Record Home Page. There will be a NEW Study ID XXX-XX . Record that number 
(XXX-XX ) on the HALT NTM cheat sheet . It is auto-generated by REDCap. You will 
need it later. 
8. The first Form to complete is Demographics. Open the form by clicking on the circle 
under Demographics. Near the top of the form under the header Pairs Survey is a link to 
the “ Finding Pairs survey .” Click on the link. You will be taken to an interactive tool 
that will help you determine if this subject is  “subject 1” or “subject 2” in this pairing. 
9. Using the letter from NJH ADx and the HA LT NTM cheat sheet, answer the questions. 
This will give you the pair number and subject number for the patients. Record those 
numbers on the HALT NTM cheat sheet. You ma y also choose to click Submit and then 
Download to get a printout of your survey responses for your record. 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 33 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
10. Back on the Demographic form, complete the que stions for the first subject in the pair. 
Have the HALT NTM cheat sheet handy. You will use it to enter the Pair Number, 
Subject Number, culture dates,  and isolate ID into REDCap . Enter as much data as you 
can. Once complete, click on Save & Exit Form button. 
11. Repeat Steps 6-9 for the s econd subject in the pair. 
12. Now that you have the demographics and so me background information entered for both 
subjects in a pair, the next Form to comp lete is Compare. You can access it from the 
Record Status Dashboard or from Add/Edit Records listed under Data Collection on the 
left hand side. 
13. Using the HALT NTM cheat sheet, answer “For this pairing, is this Subject 1 or Subject 
2?” Depending on your answer, you will be  asked to enter a date for the OTHER 
PATIENT in this pairing. Be sure to read the questions carefully a nd enter the correct 
date. 
14. Once the date has been entered, a box w ill pop-up with the Extraction Date Range. 
Record this on the HALT NTM cheat sheet. 
15. Now for the digging. In order to see if your  pair of patients had any overlap, you will 
need to enter dates for Inpatient hospitalizati ons, Outpatient Clinic visits, and Research 
Unit visits. Only record visits that fall within the Extraction Date Range. 
16. Keep digging! You’ve completed the extracti on for the first subject in the pair. Now 
repeat Steps 12-15 for the s econd subject in the pair. 
17. Once you have completed the Compare Form (all the date extractions) for a pair of 
subjects, you are ready to see if there is a ny overlap between these two patients. Click on 
“Compare Dates” on the left side under Proj ect Bookmarks. You will be asked to enter 
the internal record id ( XXX-XX) for the two subjects in the pair you are comparing. 
18. Take a deep breath and click “Compare s ubjects.” The program will let you know if 
there is any overlap in dates for Inpatient, C linic, and/or Research Visits. If there is, 
REDCap will mark those forms as red circles on the Record Status Dashboard. If there 
is no overlap, the circles will stay gr ey and you are done with this pair. 
19. However, if you have red circles on the Record Status Dashboar d, it is time to dig again. 
Clicking on a red circle will take you to an Overlap Form – there is one form for each 
location the program found date overlaps. The top of the form is uneditable, but you are 
able to see the Patient Name, Pair Number , Subject Number, and Date Range for the 
detailed data extraction. Use this informati on to complete the ques tions as best you can 
for each visit overlap ( red circle ). The more accurate you are able to be, the better the 
analysis can be. 
20. Once done, change status to “Complete,” a nd click “Save & Exit”. The status color 
changes to green on the Record Status Dashboard. You are done. 
 
 
Feel free to contact Katie or Dr. Gross for he lp along with way or if you have any comments on 
this user guide or the REDCap project. 
Protocol HALT NTM Confidential 
Version #: 1.0 Version Date: 2020_0508 Page 34 of 35 
Protocol Template: © CFFT TDN Effective: 28 APR 2017   
  
Katie Poch 
pochk@njhealth.org 
303-398-1255 
 
Dr. Jane Gross grossjane@njhealth.org 
303-270-2333 
Honda Lab Environmental  Swab Protocol ‐ General 
Adapted to JGross NJH/SJH Site Protocol_7 ‐17‐19 
1  
  
APPENDIX 3 ENVIRONMENTAL SAMPLING PROTOCOL 
 
General Environmental  Sampling  Instructions  
 
 
 
LOCATION  RECORDING  
 
Record your location at the time of sampling using GPS. Record each sampling site using a 
Google Maps on iPhone or Android. For more information:  
https://www.wikihow.com/Get ‐Latitude‐and‐Longitude ‐from‐Google‐Maps 
 
Record GPS similar to the following  and out to more than 5 significant  digits: 
NJ GPS LOCATION:  39°44'23.2"N  104°56'33.6"W  
Honda Lab Environmental  Swab Protocol ‐ General 
Adapted to JGross NJH/SJH Site Protocol_7 ‐17‐19 
2  
  
SINK FAUCET SAMPLING  
This protocol can be applied to sample water biofilms from kitchen, bathroom,  or outdoor sink 
faucets. 
BEFORE SAMPLING:  
1. Faucet should be as dry as possible 
2. Avoid sampling a faucet if it has been recently used or is wet 
3. If faucet is wet, DO NOT dry off. If possible, return to faucet at another time 
SAMPLING  
1. Identify the sink faucet and take a picture of it 
using your cell phone or camera. 
2. Obtain one of the sterile dual‐tipped Flock swabs. 
3. Identify the point of the sink faucet where water 
exits . This is where the sample should be taken. 
Note: Depending  on the faucet, there might 
be a metal mesh on the faucet head similar 
the image to the right (“Step 4 under view”). If 
so, sample the mesh. 
Note: Depending  on the faucet, there might 
be an open pipe which water will directly flow 
out of. If so, sample up into the pipe. 
4. Carefully open a new swab package. To do so, 
carefully pry open the swab package. Remove the swab by grabbing the RED handle and 
avoid laying the swab down on non‐sterile surfaces; keep the swab sterile! Be careful not to 
touch anywhere  along the swab and only handle the swab by the red handle. 
5. If mesh sampling ‐ Firmly and thoroughly  swab the point on the sink faucet where water 
exits in a back and forth motion 10 times as well as a circular motion ‐ imagine that you are 
using the swab to “clean” the surface as completely  as possible. Twist the swab over and 
sample the same surface 10 more times to ensure this side of the swab has also collected 
biofilms. Avoid moving your hand onto the white applicator  stick. 
OR 
If open pipe sampling – Insert the swab into the pipe and swab the sides of the pipe using a 
circular, firm stirring motion ‐ similar to stirring your coffee – 10 times. Twist the swab over 
and sample the same surface 10 more times to ensure all sides of the swab has collected 
pipe biofilm. Avoid moving your hand onto the white applicator  stick. 
6. Once you have collected the sample, twist and remove the cap from the sterile collection  
tube that remains in the swab package and CAREFULLY  place the soiled swab into the 
transport  tube, being careful not to touch the swab tips with your fingers. 
7. Cap tightly. Label the tube with a Sharpie or pre‐prepared label that contains at a minimum  
the following  information:  the date, your initials, sample ID, and sample type (i.e., bathroom  
sink mesh or hospital room sink faucet pipe). 
8. Place labeled tubes in a ziploc bag and refrigerate  samples until processing.  

Honda Lab Environmental  Swab Protocol ‐ General 
Adapted to JGross NJH/SJH Site Protocol_7 ‐17‐19 
3  
  
 
 
  
 
DUST SAMPLING  
1. Locate a dusty area at the sampling site – sample similar sites in all rooms of NJH and SJH. 
2. Before sampling,  take a representative  picture of the dusty area using your cell phone or 
camera. 
3. Obtain one of the sterile dual‐tipped Flock swabs. 
4. Carefully open a new swab package. To do so, carefully pry open the swab package. 
Remove the swab by grabbing the RED handle and avoid laying the swab down on non‐ 
sterile surfaces; keep the swab sterile! Be careful not to touch anywhere  along the swab 
and only handle the swab by the red handle tip. 
5. Swab across the dusty surface using a back and forth motion 10 times, imagining  that you 
are using the swab to clean the surface and remove as much dust as possible (refer to the 
image below). It often helps to rotate the tip of the swab as you brush it across the surface 
to make sure all sides of the swab get coated with visible dust. 
6. Once you have collected the sample, twist and remove the cap from the sterile collection  
tube that remains in the swab package and CAREFULLY  place the soiled dust swab into the 
transport  tube, being careful not to touch the swab tips with your fingers. 
7. Cap tightly. Label the tube with a Sharpie or pre‐prepared label that contains at a minimum  
the following  information:  the date, your initials, sample ID, and sample type (i.e., dust). 
8. Place labeled tubes in a ziploc bag and refrigerate  samples until processing.  
 

Honda Lab Environmental  Swab Protocol ‐ General 
Adapted to JGross NJH/SJH Site Protocol_7 ‐17‐19 
4  
  
SAMPLING  SHOWER HOSES AND SHOWERHEADS  
 
HOW TO SAMPLE THE HOSE (if it has a removable  showerhead):  
1. Take a representative  picture of the end of the 
showerhead  system similar to what is shown in the image 
using your cell phone or camera 
2. Carefully twist and remove the showerhead  from the 
shower hose at the connection  point labeled “1” on the 
image to the left. Do not place the showerhead  or hose 
down ; keep holding both in one of your hands. 
3. Obtain two of the sterile dual‐tipped Flock swabs. 
4. Carefully open a new swab package. To do so, carefully 
pry open the swab package. Remove the swab by grabbing 
the RED handle and avoid laying the swab down on non‐ 
sterile surfaces; keep swab sterile! Be careful not to touch 
anywhere  along the swab and only handle the swab by the red handle tip. 
5. Firmly and thoroughly,  swab the inner portion of the hose at point “2” as shown on the 
image above. Using a “stirring” motion move the swab in and around the hose opening ‐ 
imagining  that you are using the swab to clean the surface or motion similar to stirring your 
coffee. Rotate the swab as you swirl to ensure all portions of the swabs have been exposed 
to biofilms. Rotate and swab 10 times. Avoid moving your hand onto the white applicator  
stick. 
6. Once you have collected the sample from the hose, the hose can now be placed down into 
the tub or onto a counter. However,  keep holding the showerhead . Twist and remove the 
cap from the sterile collection  tube that remains in the swab package and CAREFULLY  place 
the soiled swab into the transport  tube, being careful not to touch the swab tips with your 
fingers. 
7. Cap tightly. Label the tube with a Sharpie or pre‐prepared label that contains at a minimum  
the following  information:  the date, your initials, sample ID, and sample type (i.e., 
showerhead  (SHB) hose). 
8. Place labeled tubes in a ziploc bag and refrigerate  swab until processing.  
 
HOW TO SAMPLE THE SHOWERHEAD  FACE: 
1. Carefully open a new swab package. To do so, carefully pry open the swab package. 
Remove the swab by grabbing the RED handle and avoid laying the swab down on non‐ 
sterile surfaces; keep swab sterile! Be careful not to touch anywhere  along the swab and 
only handle the swab by the red handle tip. 
2. Firmly and thoroughly,  swab the face of the showerhead  (the side from which the water 
would emerge) at point “3” as shown on the image above. Move the swab back and forth 
and around the entire surface of the showerhead  face 10 times in a circular motion ‐ 
imagining  that you are using the swab to clean the surface as completely  as possible. Don’t 
forget to get into the grooves on the showerhead  face. Twist the swab over and sample the 

Honda Lab Environmental  Swab Protocol ‐ General 
Adapted to JGross NJH/SJH Site Protocol_7 ‐17‐19 
5  
  
same surface 10 more times to ensure this side of the swab has also collected biofilms. 
Avoid moving your hand onto the white applicator  stick. 
3. It is now OK to put the showerhead  down into the tub or onto a counter. 
4. Once you have collected the sample, twist and remove the cap from the sterile collection  
tube that remains in the swab package and CAREFULLY  place the soiled swab into the 
transport  tube, being careful not to touch the swab tips with your fingers. 
5. Cap tightly. Label the tube with a Sharpie or pre‐prepared label that contains at a minimum  
the following  information  ‐ the date, your initials, sample ID, and sample type (i.e., 
showerhead  biofilm (SHB)). 
6. Place labeled tubes in a ziploc bag and refrigerate  swab until processing.  
 
HOW TO SAMPLE A NON‐REMOVABLE  SHOWERHEAD:  
 
Locate the showerhead  in your home that is most often used. Swabbing  should be done when 
then showerhead  is as dry as possible — do not use a showerhead  that has been recently used 
or is wet. 
 
1. Locate the non‐removeable  showerhead.  Take a representative  picture using your cell 
phone or camera. 
2. Carefully open a new swab package. To do so, carefully pry open the swab package. 
Remove the swab by grabbing the RED handle and avoid laying the swab down on non‐ 
sterile surfaces; keep swab sterile! Be careful not to touch anywhere  along the swab 
and only handle the swab by the red handle tip. 
3. Firmly and thoroughly,  swab the OUTSIDE SURFACE  of the showerhead  (the side from 
which the water would emerge) using a firm back and forth as well as a circular motion, 
imagining  that you are using the swab to clean the showerhead  surface as completely  as 
possible. Don’t forget to get into the grooves on the showerhead  face. Twist the swab 
over and sample the same surface 10 more times to ensure this side of the swab has 
also collected biofilms. Avoid moving your hand onto the white applicator  stick. 
4. Once you have collected the sample, twist and remove the cap from the sterile 
collection  tube that remains in the swab package and CAREFULLY  place the soiled swab 
into the transport  tube, being careful not to touch the swab tips with your fingers. 
5. Cap tightly. Label the tube with a Sharpie or pre‐prepared label that contains at a 
minimum  the following  information  ‐ the date, your initials, sample ID, and sample type 
(outside SHB). 
6. Place labeled tubes in a ziploc bag and refrigerate  swab until processing.  
Honda Lab Environmental  Swab Protocol ‐ General 
Adapted to JGross NJH/SJH Site Protocol_7 ‐17‐19 
6  
 
 
 
 
ICE MACHINE  SAMPLING  
 
1. Locate the ice machine. Take a representative  picture of the ice machine using your cell 
phone or camera. Be sure to capture both the ice and water spouts. 
2. Obtain one of the sterile dual‐tipped Flock swabs. 
3. Carefully open a new swab package. To do so, carefully pry open the swab package. 
Remove the swab by grabbing the RED handle and avoid laying the swab down on non‐ 
sterile surfaces; keep swab sterile! Be careful not to touch anywhere  along the swab and 
only handle the swab by the red handle tip. 
4. Insert the swab up into the plastic ice dispensing  “shoot” – highlighted  in red in the image 
below. 
5. Firmly and thoroughly,  swab all sides of the plastic ice 
shoot using a “stirring” motion to move the swab in 
and around the opening ‐ imagine that you are using 
the swab to methodically  clean the surface. Rotate 
the swab as you swirl to ensure all portions of the 
swab has been exposed to biofilms. Rotate and swab 
10 times. Avoid moving your hand onto the white 
applicator  stick. 
6. Once you have collected the sample, twist and remove 
the cap from the sterile collection  tube that remains in 
the swab package and CAREFULLY  place the soiled 
dust swab into the transport  tube, being careful not to 
touch the swab tips with your fingers. 
7. Cap tightly. Label the tube with a Sharpie or pre‐ 
prepared  label that contains at a minimum  the 
following  information:  the date, your initials, sample ID, and sample type (i.e., ice machine).  
8. Repeat steps 2‐7 for the water spout on the ice machine. 
9. Place labeled tubes in a ziploc bag and refrigerate  swabs until processing.  

Honda Lab Environmental  Swab Protocol ‐ General 
Adapted to JGross NJH/SJH Site Protocol_7 ‐17‐19 
7  
  
DRINKING  FOUNTAIN  SAMPLING  
 
Sampling should be done when the spigot is as dry as possible—avoid  sampling a spigot if it has 
been recently used or is wet. If spigot is wet, DO NOT dry off. If possible, return to faucet at 
another time. 
 
1. Locate the drinking fountain. Take a representative  picture of the drinking fountain using 
your cell phone or camera. 
2. Obtain one of the sterile dual‐tipped Flock swab. 
3. Carefully open a new swab package. To do so, carefully pry open the swab package. 
Remove the swab by grabbing the RED handle and avoid laying the swab down on non‐ 
sterile surfaces; keep swab sterile! Be careful not to touch anywhere  along the swab and 
only handle the swab by the red handle tip. 
 
 
4. If mesh sampling ‐ Firmly and thoroughly  swab the point on the spigot where water exits in 
a back and forth motion 10 times as well as a circular motion ‐ imagine that you are using 
the swab to “clean” the surface as completely  as possible. Twist the swab over and sample 
the same surface 10 more times to ensure this side of the swab has also collected biofilms. 
Avoid moving your hand onto the white applicator  stick. 
OR 
If open pipe sampling – Insert the swab into the pipe and swab the sides of the pipe using a 
circular, firm stirring motion ‐ similar to stirring your coffee – 10 times. Twist the swab over 
and sample the same surface 10 more times to ensure all sides of the swab has collected 
pipe biofilm. Avoid moving your hand onto the white applicator  stick. 
5. Once you have collected the sample, twist and remove the cap from the sterile collection  
tube that remains in the swab package and CAREFULLY  place the soiled swab into the 
transport  tube, being careful not to touch the swab tips with your fingers. 
6. Cap tightly. Label the tube with a Sharpie or pre‐prepared label that contains at a minimum  
the following  information:  the date, your initials, sample ID, and sample type (i.e., left 
drinking fountain).  
7. Place labeled tubes in a ziploc bag and refrigerate  samples until processing.  

Honda Lab Environmental  Swab Protocol ‐ General 
Adapted to JGross NJH/SJH Site Protocol_7 ‐17‐19 
8  
  
Honda Lab Environmental  Swab Protocol ‐ General 
Adapted to JGross NJH/SJH Site Protocol_7 ‐17‐19 
9  
  
WATER FEATURE SAMPLING  
 
1. Locate the water feature. It may be a fountain, pool, or water wall. Take a representative  
picture of the water feature before sampling using your cell phone or camera. 
2. Obtain one of the sterile dual‐tipped Flock swabs. 
3. Carefully open a new swab package. To do so, carefully pry open the swab package. 
Remove the swab by grabbing the RED handle and avoid laying the swab down on non‐ 
sterile surfaces; keep swab sterile! Be careful not to touch anywhere  along the swab and 
only handle the swab by the red handle tip. 
4. Sample the dry “scumline”  (see image of a pool below) – located at the air‐water interface.  
Rotate the swab around as you sample the dry area right above the water line (see image of 
a pool below) and ensure all portions of the swab has been exposed to the biofilm. Rotate 
and swab 10 times. Avoid moving your hand onto the white applicator  stick. 
5. Once you have collected the sample, twist and remove the cap from the sterile collection  
tube that remains in the swab package and CAREFULLY  place the soiled swab into the 
transport  tube, being careful not to touch the swab tips with your fingers. 
6. Cap tightly. Label the tube with a Sharpie or pre‐prepared label that contains at a minimum  
the following  information:  the date, your initials, sample ID, and sample type (i.e., water 
feature). 
7. Place labeled tubes in a ziploc bag and refrigerate  swabs until processing.  
 
